Skip to main content

23andMe Appoints Board Certified Genetic Counselor Erynn Gordon to 23andMe’s Management Team

March 19, 2015

Erynn Gordon to Oversee Engagement with Medical Community and Key Clinical Applications as Medical Marketing Director

Mountain View, Calif. – March 19, 2015 – 23andMe, Inc., the leading personal genetics company, today announced the appointment of Erynn Gordon, MS, CGC as medical marketing director.

Gordon is a board certified genetic counselor with more than 14 years of clinical and research experience in genetics. Gordon has also served as president of the American Board of Genetic Counseling (ABGC), chair of the ethics advisory board of the National Society of Genetic Counselors (NSGC) and is currently serving as vice chair of the New Jersey Board of Medical Examiners’ Genetic Counseling Advisory Committee. In her role at 23andMe, Gordon will oversee engagement with the medical community, as well as strategic initiatives at 23andMe related to clinical applications.

In this capacity, Gordon joins the newly created commercial marketing group led by Ruby Gadelrab, vice president of commercial marketing. Gordon will also work closely with 23andMe’s chief medical officer, Jill Hagenkord, MD and her medical affairs team. Both Gadelrab and Hagenkord are leading 23andMe’s efforts to engage the medical and scientific communities.

“As a board certified genetic counselor, Erynn brings a level of experience and expertise that will help 23andMe strengthen our relationships within the medical community,” said 23andMe chief medical officer, Jill Hagenkord, MD. “Her experience across various sectors of the health care system will help our team engage the community more deeply by promoting education and understanding of human genetics.”

Before joining 23andMe, Gordon was a lead genetic counselor and medical liaison on the commercial team at Invitae. Prior to this, she was director of genetic counseling at the Coriell Institute for Medical Research where she managed the Coriell Personalized Medicine Collaborative. In this role, she conducted research on motivations, perceptions and behaviors of early adopters of personalized medicine, and developed educational resources for patients and health care providers. She also forged collaborative relationships and integrated personalized medicine into a variety of settings, including the United States Air Force Medical Service and academic medical centers.

“The reach that 23andMe has is remarkable and really moves genetics from clinics and labs into the hands of everyone,” said Gordon. “To ensure everyone can benefit from their genetic information, health care providers have an opportunity to play a larger role in utilizing genetics in patient management. I’m looking forward to engaging the health care provider community in this conversation, and developing resources to support the use of genetics in clinical care.”

Gordon holds a Master’s of Science in Genetic Counseling from the University of Pittsburgh, PA, and a Bachelor of Arts degree in Biology and Psychology from Lehigh University in Bethlehem, PA.

About 23andMe

23andMe, Inc., headquartered in Sunnyvale, CA, is a leading consumer genetics and research company. Founded in 2006, the company’s mission is to help people access, understand, and benefit from the human genome. 23andMe has pioneered direct access to genetic information as the only company with multiple FDA clearances for genetic health reports. The company has created the world’s largest crowdsourced platform for genetic research, with 80% of its customers electing to participate. The 23andMe research platform has generated more than 180 publications on the genetic underpinnings of a wide range of diseases. The platform also powers the 23andMe Therapeutics group, currently pursuing drug discovery programs rooted in human genetics across a spectrum of disease areas, including oncology, respiratory, and cardiovascular diseases, in addition to other therapeutic areas. More information is available at